ResoTher Pharma A/S: Financial statements 2021
CVR: 37852406
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2021. In 2021, the company reported a net result of DKK -11,678,000 compared with DKK -5,196,000 the year before. Equity in the 2021 report amounted to DKK 38,631,000. The solvency ratio was 93.3%. The company had 3 employees in the financial year.
- Profit/Loss
- DKK -11,678,000
- Equity
- DKK 38,631,000
- Total Assets
- DKK 41,406,000
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | - | -11.7M | 38.6M | 3 |
| 2020 | - | - | -5.2M | -560K | 2 |
| 2019 | - | - | -3.9M | 1.7M | - |
| 2018 | - | -2.1M | -2.4M | -1.5M | 1 |
Official annual report
Find more companies like ResoTher Pharma A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
As of December 15, 2021, Quantass ApS is registered as an owner of ResoTher Pharma A/S with an ownership share of 5%.
As of December 15, 2021, TJ Biotech Holding ApS is registered as an owner of ResoTher Pharma A/S with an ownership share of 5%.
ResoTher Pharma A/S has published its annual report for 2020. The net result was DKK -5,196,000.
As of May 31, 2021, Thomas Feldthus has joined the board of directors of ResoTher Pharma A/S.
As of May 31, 2021, Sven Martin Jacobson has joined the board of directors of ResoTher Pharma A/S.
As of May 31, 2021, Lars Henning Stigel has left the board of directors of ResoTher Pharma A/S.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.